EBMT Annual report 2023



<u>ScienceEducationPatient Care & Advocacy</u>
Our SocietyOur Mission, Vision & ValuesEBMT Membership 2023Organisational
Structure 2023Financial Highlights 2023EBMT Partners

Breadcrumb

1. Home

Entity Print



Annalisa Ruggeri CTIWP Chair Italy

Major achievements

The CTIWP activities are constantly increasing in line with the advance in HCT, cell and gene therapy fields.

The collaboration with the different working parties and partner society (GoCART, EHA) is ongoing with the aim to harmonise the practice and the workload in the cell

therapy field. The activity in the harmonisation of the accreditation process for centres that perform CAR T therapies in collaboration with JACIE and GoCART, to avoid duplication of efforts (Reduced CART site qualification workload for JACIE accredited centres | EBMT).

The research activity is broad and dedicated to the immunogenetics to evaluate new factors on HLA expression level and typing able to improve transplant outcomes, and the role of HLA in the new post transplant cyclophosphamide approach. The immunomonitoring after CAR T as well the impact of possible exposure of antibiotics on the results of CART in patients with lymphomas, is under evaluation with surveys to dedicated centres. Another important field of research is to develop a consensus of the use of other cellular therapies, such as donor lymphocyte infusion according to the different donor types and stem cell source.

Principal research studies

State-of-the art of immune monitoring procedures after chimeric antigen receptor T-cell therapies in EBMT centers

Study type

Closed Survey/Study

Diseases

All diseases

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

CAR T

Principal investigator

Simona Pagliuca

Survey on the use of DLI after allogeneic after allogeneic stem cell transplantation

across EBMT centers

Study type

Closed Survey/Study

Diseases

All diseases

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Donor Leukocyte Infusion (DLI)

Principal investigator

Nicole Santoro

Potential factors influencing CAR-T cell manufacturing in terms of production failures and out of specification (OOS) products on behalf of EBMT - CTIWP

Study type

Closed Survey/Study

Diseases

All diseases

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

CAR T

Principal investigator

Nina Worel

Impact of the Addition of Antithymocyte Globulin to Post-Transplantation

Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood

Compared to Post-Transplantation Cyclophosphamide Alone: A Retrospective Study

on Behalf of the CTIWP

Study type

Retrospective Studies

<u>Diseases</u>

Acute Lymphatic Leukaemia (ALL)

Acute Myeloid Leukaemia (AML)

Chronic Lymphocytic Leukaemia (CLL)

Chronic Myeloid Leukaemia (CML)

Chronic Lymphocytic Leukaemia (CLL)

Myelodysplastic (MDS) or MDS/MPN

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Allogeneic - Haploidentical

Principal investigator

Antoine Capes

Defining protective immune cell subsets and subpopulations thresholds following allogeneic hematopoietic stem cell transplantation

Study type

Retrospective Studies

<u>Diseases</u>

All diseases

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

<u>Allogeneic</u>

Principal investigator

Marina Cavazzana

Key publications

2023

<u>Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey</u>

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Other society

1st listed author

P Comoli

Journal

Ann Oncol.

2023

Impact of allele-level HLA matching on outcomes after double cord blood

transplantation in adults with malignancies

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Other society

1st listed author

Giancarlo Fatobene

<u>Journal</u>

Blood Adv.

2023

<u>Current use of fecal microbiota transfer in patients with hematologic diseases: a</u> survey on behalf of the Cellular Therapy and Immunobiology Working Party of the

EBMT

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

1st listed author

Giorgia Battipaglia

Journal

Bone Marrow Transplant.

2023

Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP)

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

Infectious Diseases Working Party (IDWP)

1st listed author

N Worel

Journal

Bone Marrow Transplant.

2023

Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

1st listed author


M A de Witte

<u>Journal</u>

Bone Marrow Transplant.

See the full list of the CTIWP 2023 publications






2021 2022 2023

Oral presentations 4 2 7
Poster presentations 2 4 4
Educational events 5 7 7



Event



Event

EBMT-EHA 5th European CAR T-cell Meeting

Feb 09, 2023 - Feb 11, 2023 / Rotterdam & Online, Netherlands Discover more



Event

Educational Meeting on Immunology and Cellular Therapy in Plasma Cell Disorders

Nov 24, 2023 - Nov 26, 2023 / Hamburg, Germany Discover more

- 49th Annual Meeting of the EBMT: Cell Therapy Day
- 49th Annual Meeting of the EBMT: CTIWP session
- 49th Annual Meeting of the EBMT: CTIWP Scientific Business Meeting
- DLI Harmonisation Workshop Lille
- CTIWP Scientific Business Meeting Hamburg

VISIT THE CTIWP WEBPAGE